特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
611086

世界の腎臓癌市場の分析と予測

Global Kidney Cancer Market Research and Forecast 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
世界の腎臓癌市場の分析と予測
出版日: 2018年02月01日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、腎臓癌の世界市場について調査し、市場の概要、種類・腎細胞癌タイプ・診断法・治療法・地域別の市場動向、市場規模の推移と予測、市場促進要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 レポート概要

  • 調査手法
  • 市場区分
    • セグメント別
    • 地域別
    • ステークホルダー別

第2章 市場概要と考察

  • 市場の定義
  • アナリストによる考察と市場動向
    • 主な所見
    • 提言
    • 総論
  • 規制動向
    • 米国
    • 欧州
    • 中国
    • インド
  • 特許分析

第3章 市場の決定要因

  • 市場促進要因
  • 市場阻害要因
  • 市場機会

第4章 腎臓癌市場:市場区分

  • 種類別
    • 腎細胞癌(RCC)
    • 移行上皮癌
    • 腎芽腫(ウィルムス腫瘍)
    • その他(腎肉腫、リンパ腫)
  • 腎細胞癌タイプ別
    • 淡明細胞型腎細胞癌
    • 乳頭状腎細胞癌
    • その他
  • 診断法別
    • 生検
    • CTスキャン
    • MRI
    • 超音波検査
  • 治療法別
    • 手術
    • 免疫療法
    • 化学療法
    • 放射線治療
    • 凍結療法

第5章 競合環境

  • 主要戦略
  • 主要企業の分析

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • ABBVIE INC
  • ACTIVE BIOTECH AB
  • ACTUATE THERAPEUTICS INC
  • ADAPTIMMUNE THERAPEUTICS PLC
  • AMGEN INC
  • ASTRAZENECA PLC
  • BAYER PHARMA AG
  • CIPLA LIMITED
  • エーザイ
  • EXELIXIS, INC.
  • GENENTECH, INC.
  • GLAXOSMITHKLINE PLC
  • HOFFMAN-LA ROCHE
  • JAZZ PHARMACEUTICALS, INC.
  • MERCK & CO.
  • NOVARTIS AG
  • ONYX
  • PFIZER INC.
  • PROMETHEUS LABORATORIES INC
  • SANOFI
  • 武田薬品工業
図表

List of Tables

  • TABLE # 1 GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL RENAL CELL CARCINOMA (RCC) KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL TRANSITIONAL CELL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL WILM'S TUMOUR MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL OTHER KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER CELL 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL CLEAR CELL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL PAPILLARY KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL OTHER KIDNEY CANCER CELL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL KIDNEY CANCER BIOPSY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL KIDNEY CANCER COMPUTED TOMOGRAPHY (CT) SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL KIDNEY CANCER MAGNETIC RESONANCE IMAGING (MRI) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL KIDNEY CANCER ULTRASOUND MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 16 GLOBAL KIDNEY CANCER SURGERY MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023 ($ MILLION)
  • TABLE # 17 GLOBAL KIDNEY CANCER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 18 GLOBAL KIDNEY CANCER CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 19 GLOBAL KIDNEY CANCER RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 20 GLOBAL KIDNEY CANCER CRYOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 21 NORTH AMERICA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 22 NORTH AMERICA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
  • TABLE # 23 NORTH AMERICA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023 ($ MILLION)
  • TABLE # 24 NORTH AMERICA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER CELL, 2017-2023 ($ MILLION)
  • TABLE # 25 NORTH AMERICA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
  • TABLE # 26 EUROPE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 27 EUROPE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
  • TABLE # 28 EUROPE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023 ($ MILLION)
  • TABLE # 29 EUROPE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER CELL 2017-2023 ($ MILLION)
  • TABLE # 30 EUROPE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
  • TABLE # 31 ASIA PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 32 ASIA PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
  • TABLE # 33 ASIA PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023 ($ MILLION)
  • TABLE # 34 ASIA PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER CELL 2017-2023 ($ MILLION)
  • TABLE # 35 ASIA PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL KIDNEY CANCER MARKET SHARE, BY CANCER TYPE 2017 VS 2023 ($ MILLION)
  • FIGURE # 2 GLOBAL KIDNEY CANCER MARKET SHARE, BY DIAGNOSTIC METHOD 2017 VS 2023 ($ MILLION)
  • FIGURE # 3 GLOBAL KIDNEY CANCER MARKET SHARE, BY THERAPY 2017 VS 2023 ($ MILLION)
  • FIGURE # 4 GLOBAL KIDNEY CANCER MARKET SHARE, BY CANCER CELL 2017 VS 2023 ($ MILLION)
  • FIGURE # 5 GLOBAL KIDNEY CANCER MARKET SHARE, BY GEOGRAPHY 2017 VS 2023 ($ MILLION)
  • FIGURE # 6 NORTH AMERICA KIDNEY CANCER MARKET SHARE, 2017-2023($ MILLION)
  • FIGURE # 7 UNITED STATES KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 8 CANADA MARKET KIDNEY CANCER RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 9 EUROPE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • FIGURE # 10 UK KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 11 GERMANY KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 12 SPAIN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 13 FRANCE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 14 ITALY KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 15 ROE KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 16 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • FIGURE # 17 CHINA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 18 INDIA KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 19 JAPAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 20 REST OF ASIA PACIFIC (ROAPAC) KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 21 REST OF WORLD (ROW) KIDNEY CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
目次
Product Code: OMR2017227

Kidney cancer is one of the most common cancers across the globe. Most of the kidney cancers get diagnosed before they metastasize to distant organs. However, the tumours can grow to be quite large before they are detected. The global kidney cancer market is estimated to grow with the CAGR of 6.2% during 2018-2023. The growth of the market is attributed to increasing incidence of kidney cancers and increasing ill lifestyle changes which gets worsen with addiction of tobacco and alcohol. Furthermore, overexposure to radiation during treatment testicular cancer, growing awareness program, and increasing mortality due to kidney cancer are boosting the kidney cancer market.

However, high cost associated with the treatment is the major restrain to the market. Generally, kidney cancer can cause in the range of $15,000 to $75,000. Various companies are getting FDA approval for kidney cancer and number of drugs is in clinical trial for the same. Hence innovation in drug development, and subsequent technological advancements & pipeline product finds an immense opportunity in near future.

On the basis of geography, the market has been divided into North America, Europe, Asia Pacific and Rest of the World. Europe is expected to dominate in the global kidney cancer market owing to high prevalence of kidney cancer in the UK, France, Germany and other EU countries. High prevalence of kidney cancer, high consumption of alcohol and tobacco are the major factor driving the market. North America and Asia Pacific are also expected to have a major market share during the forecast period. The major countries contributing in the APAC region are China, Australia, Japan and India. Large customer base, high consumption of Tabaco, continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. In North America, the US and Canada are expected to have a major market share in the region. As per National Cancer Institute kidney cancer is the 8th leading cancer in the US in 2017 with a share of around 4%.

A number of pharmaceutical companies are active in kidney cancer market. The major companies active in the market are Merck, Novartis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Roche and so on. The companies are focusing on product innovations, expansions, M&A, finding new market or innovate in their core competency in order to expand individual market share. The report includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, market determinants, market segmentation and company profiling of the market.

Market Segmentation:

  • Global Kidney Cancer market is segmented on the basis of regional outlook and following segments:
  • Global Kidney Cancer Market Research and Analysis, By Cancer Type
  • Global Kidney Cancer Market Research and Analysis, By Cancer Cell
  • Global Kidney Cancer Market Research and Analysis, By Diagnosis
  • Global Kidney Cancer Market Research and Analysis, By Therapy
  • Global Kidney Cancer Market Research and Analysis, By Region

The Report covers:

  • Comprehensive research methodology of Global Kidney Cancer Market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the

Global Kidney Cancer Market.

  • Insights about market determinants which are stimulating the Global Kidney Cancer Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

  • 1. REPORT SUMMARY
  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
  • 1.2.1. BY SEGMENTS
  • 1.2.2. BY GEOGRAPHY
  • 1.2.3. BY STAKEHOLDERS
  • 1.2.4. EXCEPTIONS
  • 2. MARKET OVERVIEW AND INSIGHTS
  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
  • 2.2.1. KEY FINDINGS
  • 2.2.2. RECOMMENDATION
  • 2.2.3. CONCLUSION
  • 2.3. PATENT ANALYSIS
  • 2.4. REGULATION
  • 2.4.1.1. UNITED STATES
  • 2.4.1.2. EUROPEAN UNION
  • 2.4.1.3. CHINA
  • 2.4.1.4. INDIA
  • 3. MARKET DETERMINANT
  • 3.1. MOTIVATORS
  • 3.1.1. HIGH PREVALENCE OF KIDNEY CANCER
  • 3.1.2. LIFESTYLE CHANGES AND ADDICTION OF TOBOCCO AND OTHER HARMFUL SUBSTANCE
  • 3.1.3. OVER EXPOSURE OF RADIATION DURING TESTICULAR CANCER
  • 3.1.4. INCREASING GOVERNMENT AWARENESS PROGRAMS
  • 3.1.5. R&D AND GROWING GOVERNMENT GRANTS AND FUNDING
  • 3.2. RESTRAINTS
  • 3.2.1. HIGH COST ASSOCIATED WITH VARIOUS THERAPIES
  • 3.2.2. UNFAVORABLE REIMBURSEMENT POLICIES
  • 3.3. OPPORTUNITIES
  • 3.3.1. INNOVATION IN DRUG DEVELOPMENT
  • 3.3.2. SUBSEQUENT TECHNOLOGICAL ADVANCEMENTS & GROWING PIPELINE PRODUCTS
  • 4. MARKET SEGMENTATION
  • 4.1. GLOBAL KIDNEY CANCER MARKET, BY CANCER TYPE
  • 4.1.1. RENAL CELL CARCINOMA (RCC)
  • 4.1.2. TRANSITIONAL CELL CANCER
  • 4.1.3. WILM'S TUMOUR (NEPHROBLASTOMA)
  • 4.1.4. OTHER (SARCOMA, LYMPHOMA)
  • 4.2. GLOBAL KIDNEY CANCER MARKET, BY CANCER CELL
  • 4.2.1. CLEAR CELL
  • 4.2.2. PAPILLARY
  • 4.2.3. OTHER (CHROMOPHOBE, ONCOCYTOMA, ANGIOMYOLIPOMA, MEDULLARY, SARCOMATOID FEATURES)
  • 4.3. GLOBAL KIDNEY CANCER MARKET, BY DIAGNOSIS METHOD
  • 4.3.1. BIOPSY
  • 4.3.2. COMPUTED TOMOGRAPHY (CT) SCAN
  • 4.3.3. MAGNETIC RESONANCE IMAGING (MRI)
  • 4.3.4. ULTRASOUND
  • 4.4. GLOBAL KIDNEY CANCER MARKET, BY THERAPY
  • 4.4.1. SURGERY
  • 4.4.2. IMMUNOTHERAPY
  • 4.4.3. CHEMOTHERAPY
  • 4.4.4. RADIATION THERAPY
  • 4.4.5. CRYOTHERAPY
  • 5. COMPETITIVE LANDSCAPE
  • 5.1. KEY STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS
  • 6. REGIONAL ANALYSIS
  • 6.1. NORTH AMERICAN
  • 6.1.1. UNITED STATES
  • 6.1.2. CANADA
  • 6.2. EUROPE
  • 6.2.1. UK
  • 6.2.2. GERMANY
  • 6.2.3. SPAIN
  • 6.2.4. FRANCE
  • 6.2.5. ITALY
  • 6.2.6. REST OF EUROPE
  • 6.3. APAC
  • 6.3.1. INDIA
  • 6.3.2. CHINA
  • 6.3.3. JAPAN
  • 6.3.4. REST OF APAC
  • 6.4. REST OF THE WORLD
  • 7. COMPANY PROFILES
  • 7.1. ABBVIE INC
  • 7.2. ACTIVE BIOTECH AB
  • 7.3. ACTUATE THERAPEUTICS INC
  • 7.4. ADAPTIMMUNE THERAPEUTICS PLC
  • 7.5. AMGEN INC
  • 7.6. ASTRAZENECA PLC
  • 7.7. BAYER PHARMA AG
  • 7.8. CIPLA LIMITED
  • 7.9. EISAI CO., LTD.
  • 7.10. EXELIXIS, INC.
  • 7.11. GENENTECH, INC.
  • 7.12. GLAXOSMITHKLINE PLC
  • 7.13. HOFFMAN-LA ROCHE
  • 7.14. JAZZ PHARMACEUTICALS, INC.
  • 7.15. MERCK & CO.
  • 7.16. NOVARTIS AG
  • 7.17. ONYX
  • 7.18. PFIZER INC.
  • 7.19. PROMETHEUS LABORATORIES INC
  • 7.20. SANOFI
  • 7.21. TAKEDA PHARMACEUTICAL COMPANY LIMITED
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.